Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma

Clinical Cancer Research

Volumn 21, Issue 14, 2015, Pages 3307-3317

  Di Stefano, Anna Luisa ^a,b,c   Fucci, Alessandra ^d   Frattini, Veronique ^d   Labussiere, Marianne ^a   Mokhtari, Karima ^a,b,e   Zoppoli, Pietro ^d   Marie, Yannick ^a,f   Bruno, Aurelie ^a   Boisselier, Blandine ^a   Giry, Marine ^a   Savatovsky, Julien ^g   Touat, Mehdi ^h   Belaid, Hayat ^e   Kamoun, Aurelie ⁱ   Idbaih, Ahmed ^a,b   Houillier, Caroline ^b   Luo, Feng R ^j   Soria, Jean Charles ^h   Tabernero, Josep ^k   Eoli, Marica ^l   Paterra, Rosina ^l   Yip, Stephen ^m   Petrecca, Kevin ⁿ   Chan, Jennifer A ^o   Finocchiaro, Gaetano ^l   Lasorella, Anna ^d   Sanson, Marc ^a,b   Iavarone, Antonio ^d   more..

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF PAVIA   (Italy)

^d Howard Hughes Medical Institute   (United States)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^g FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ Programme Cartes d'Identite des Tumeurs CIT   (France)

^j JOHNSON AND JOHNSON   (United States)

^k VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^l DEPARTMENT OF NEUROSURGERY   (Italy)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ MCGILL UNIVERSITY   (Canada)

^o UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; ERDAFITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HYBRID PROTEIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PROTEIN TACC3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FGFR3 PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; JNJ-42756493; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PYRAZOLE DERIVATIVE; QUINOXALINE DERIVATIVE; TACC3 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHENIA; CANCER GRADING; CANCER INHIBITION; CDK4 GENE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSGEUSIA; EGFR GENE; FEMALE; FGFR3 GENE; GENE; GENE AMPLIFICATION; GENE FREQUENCY; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPHOSPHATEMIA; IDH1 GENE; IDH2 GENE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KERATITIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TACC3 GENE; TUMOR XENOGRAFT; XEROSTOMIA; ANIMAL; BRAIN NEOPLASMS; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; KAPLAN MEIER METHOD; MOLECULARLY TARGETED THERAPY; MORTALITY; NUDE MOUSE; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; PYRAZOLES; QUINOXALINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929114925     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2199     Document Type: Article

References (38)

1. Medves S, Demoulin JB. Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med 2012;16:237-48.
2. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007;7:233-45.
3. Weathers SP, Gilbert MR. Advances in treating glioblastoma. F1000Prime Rep 2014;6:46.
4. Omuro A, De Angelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013;310:1842-50.
5. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150-4.
6. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012;337:1231-5.
7. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.
8. Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 2013;230:270-6.
9. Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 2013;123:855-65.
10. Wang R, Wang L, Li Y, Hu H, Shen L, Shen X, et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res 2014;20:4107-14.
11. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013;22:795-803.
12. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013;3:636-47.
13. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, et al. Wholegenome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013;45:602-12.
14. Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, et al. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res 2014;20:6551-8.
15. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun 2014;5:4846.
16. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, et al. Tumor heterogeneity is an active process maintained by a mutant EGFRinduced cytokine circuit in glioblastoma. Genes Dev 2010;24:1731-45.
17. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011;20:810-7.
18. Ene CI, Fine HA. Many tumors in one: a daunting therapeutic prospect. Cancer Cell 2011;20:695-7.
19. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 2013;110:4009-14.
20. Kindich R, Florl AR, Jung V, Engers R, Muller M, Schulz WA, et al. Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. Clin Chem 2005;51:649-52.
21. Bulusu KC, Tym JE, Coker EA, Schierz AC, Al-Lazikani B. canSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Res 2014;42:D1040-7.
22. Reyes-Botero G, Giry M, Mokhtari K, Labussiere M, Idbaih A, Delattre JY, et al. Molecular analysis of diffuse intrinsic brainstem gliomas in adults. J Neurooncol 2014;116:405-11.
23. Labussière M, Boisselier B, Mokhtari K, Di Stefano AL, Rahimian A, Rossetto M, et al. Combined analysis of TERT, EGFR and IDH status define distinct prognostic glioblastoma classes. Neurology 2014;83:1200-6.
24. Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussiere M, Lesimple T, et al. Comparative assessment of 5 methods (methylationspecific polymerase chain reaction, MethyLight, pyrosequencing, methylationsensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118:4201-11.
25. Idbaih A, Aimard J, Boisselier B, Marie Y, Paris S, Criniere E, et al. Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma. Neuropathol Appl Neurobiol 2009;35:208-13.
26. Idbaih A, Marie Y, Lucchesi C, Pierron G, Manie E, Raynal V, et al. BAC array CGHdistinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 2008;122:1778-86.
27. Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 2012;18:5203-11.
28. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72.
29. Hoang-Xuan K, He J, Huguet S, Mokhtari K, Marie Y, Kujas M, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 2001;57:1278-81.
30. Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, et al. Prognostic impact of molecularmarkers in a series of 220 primary glioblastomas. Cancer 2006;106:2218-23.
31. Goldman M, Craft B, Swatloski T, Ellrott K, Cline M, Diekhans M, et al. The UCSC cancer genomics browser: update 2013. Nucleic Acids Res 2013;41:D949-54.
32. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462-77.
33. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72.
34. Bahleda R, Dienstmann R, Adamo B, Gazzah A, Infante JR, Zhong B, et al. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014;32: suppl; abstr 2501.
35. Squires M, Ward G, Saxty G, Berdini V, Cleasby A, King P, et al. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models. Mol Cancer Ther 2011;10:1542-52.
36. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
37. Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusionMR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746-55.
38. Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, et al. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol 2009;27:1005-11.